Frontlight ResearchEarly access
CompletedNo phase
The Effect of Laparoscopic Splenectomy on the Immune Function for Cirrhosis Patients
Key facts
- Who runs it
- Northern Jiangsu People's Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 21 people enrolled
- Started
- 1 Mar 2022
- Ended
- 30 Nov 2024
- Type of study
- Interventional
- Treatments tested
- Laparoscopic splenectomy
- Record updated
- 19 March 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- A clinical, radiological or histologic diagnosis of cirrhosis of any etiology
- Splenomegaly with secondary hypersplenism, Platelet count < 50*10\^9/L
- Informed consent to participate in the study
Who cannot take part
- Hepatocellular carcinoma or any other malignancy,
- Recent peptic ulcer disease
- History of Hemorrhagic stroke
- Uncontrolled Hypertension
- Bleeding portal hypertension
- Human immunodeficiency virus (HIV) infection
- Child-Pugh grade C
- Pregnancy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
In this study, the investigators compared the improvement of and azygoportal disconnection related indicators in patients with liver cirrhosis after laparoscopic splenectomy. To determine whether surgical treatment can help enhance postoperative immune function and improve patient prognosis.
The group in the trial
- Laparoscopic splenectomyTreatment being tested
The laparoscopic splenectomy is performed by the same surgical team.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 19 March 2025